ABL Bio
is a biotech research company that develops therapeutic drugs for immuno-oncology and neurodegenerative diseases... Read moreABL Bio
is a biotech research company that develops therapeutic drugs for immuno-oncology and neurodegenerative diseases... Read more
News
Apr 11, 2025
Post Online Media
ABL Bio: ABL Bio lands $2.8 licensing agreement with GSK
Apr 10, 2025
Korea Biomedical Review
ABL Bio: ABL Bio held back its top Alzheimer's targets. GSK still signed a $2.7 bil. licensing deal.
Apr 08, 2025
Pharmabiz
ABL Bio: ABL Bio enters GrabodyB brain delivery platform license pact with GSK to develop novel medicines for neurodegenerative diseases
Apr 07, 2025
PMLiVE
ABL Bio: GSK and ABL Bio enter neurodegenerative disease agreement worth over 2bn
Apr 07, 2025
BioSpace
ABL Bio: GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
Apr 02, 2025
Korea Biomedical Review
ABL Bio: Compass touts ABL Bio-partnered bispecific after pivotal trial success in biliary tract cancer
Mar 20, 2025
Korea Biomedical Review
ABL Bio: ABL Bio expands ABL103 trial, adding Keytruda and chemo in solid tumors
Jan 24, 2025
Korea Biomedical Review
ABL Bio: ABL Bio nears 1 tril. deal with global pharma firm, poised to surpass Sanofi agreement: CEO
Jan 07, 2025
Korea Biomedical Review
ABL Bio: ABL Bio's anticancer drug candidate emerges as US partner's core pipeline
Nov 06, 2024
Korea Biomedical Review
ABL Bio: ABL Bio-LigaChem's P1 trial of ADC for advanced lymphoma proceeds smoothly
ABL Bio Competitors
1
2
3
4
5
6
7
8
9
10